Holen Sie sich die Stockscreener-App
41.45
2.17%
0.88
Vorhandelsmarkt:
41.25
-0.20
-0.48%
Qiagen Nv Aktie (QGEN) Neueste Nachrichten
Qiagen stock trades steadily as molecular diagnostics growth supports margins - Ad-hoc-news.de
Qiagen N.V. $QGEN Shares Acquired by Swiss National Bank - MarketBeat
Capula Management Ltd Purchases New Stake in Qiagen N.V. $QGEN - MarketBeat
Qiagen stock steadies as latest results highlight margin resilience and cash flow strength - Ad-hoc-news.de
Qiagen stock trades steadily as investors weigh recent earnings and molecular diagnostics growth - Ad-hoc-news.de
Qiagen stock holds steady as 2025 revenue and profit metrics frame the setup - Ad-hoc-news.de
Hsbc Holdings PLC Invests $12.92 Million in Qiagen N.V. $QGEN - MarketBeat
Qiagen stock steadies as investors weigh recent earnings and molecular diagnostics growth - Ad-hoc-news.de
PTA-PVR: QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG - TradingView
Release according to Article 40, Section 1 of the WpHG - TradingView
KKR (KKR) Launches Allyntra While Chasing DStelecom And Qiagen - Yahoo Finance
Qiagen stock trades steady as diagnostics revenue grows and margin focus intensifies - Ad-hoc-news.de
Qiagen stock trades steady as diagnostics demand supports earnings momentum - Ad-hoc-news.de
Qiagen stock trades steady as diagnostics demand supports recent earnings - Ad-hoc-news.de
Qiagen stock holds firm as diagnostics demand supports revenue growth - Ad-hoc-news.de
Qiagen stock trades steady as recent results highlight margin resilience - Ad-hoc-news.de
Qiagen stock rises on recent results and market data - Ad-hoc-news.de
Baader Bank Aktiengesellschaft Buys New Stake in Qiagen N.V. $QGEN - MarketBeat
Qiagen stock trades steadily as diagnostics demand supports earnings and cash flow - Ad-hoc-news.de
Qiagen stock trades steadily as recent earnings and margin trends shape investor focus - Ad-hoc-news.de
Qiagen stock trades steady as investors weigh recent earnings and diagnostics demand - Ad-hoc-news.de
Qiagen N.V. (QGEN) Stock Analysis: Evaluating The 7.09% Upside Potential For Investors - DirectorsTalk Interviews
DekaBank Deutsche Girozentrale Takes $10.81 Million Position in Qiagen N.V. $QGEN - MarketBeat
Qiagen stock holds as investors await fresh numbers - Ad-hoc-news.de
Qiagen stock trades steady as latest quarterly numbers highlight margin resilience - Ad-hoc-news.de
William Blair Initiates Qiagen NV(QGEN.US) With Hold Rating - Moomoo
Qiagen stock trades steadily as recent earnings and guidance frame valuation - ad-hoc-news.de
Qiagen stock steadies as investors weigh Q2 2025 earnings and diagnostics demand - ad-hoc-news.de
Qiagen stock rises on 2025 results and 2026 guidance - ad-hoc-news.de
Qiagen stock trades steady as diagnostics demand supports earnings and cash flow - Ad-hoc-news.de
BlackRock Builds Significant Stake in Qiagen, Boosting Institutional Presence - The Globe and Mail
Citigroup Discloses 2.85% Stake in QIAGEN via AFM Filing - The Globe and Mail
Citigroup Reports 3.09% Indirect Stake in Qiagen via AFM Filing - The Globe and Mail
Goldman Sachs discloses 3.5% voting interest in Qiagen - The Globe and Mail
Qiagen stock holds ground as investors look to next earnings after steady 2024 revenue - ad-hoc-news.de
Allspring Global Investments Holdings LLC Has $100.21 Million Position in Qiagen N.V. $QGEN - MarketBeat
Qiagen stock holds near recent levels as earnings metrics guide the story - ad-hoc-news.de
Qiagen stock holds steady as 2026 guidance and margins stay central - ad-hoc-news.de
Qiagen (QGEN) Investor presentation Summary - Quartr
Qiagen stock trades steady as Q1 2026 growth and margin resilience underpin outlook - ad-hoc-news.de
Qiagen stock trades steady as investors weigh Q1 2024 growth and margin trends - ad-hoc-news.de
Cancer Biomarkers Market to Reach US$ 54.48 Billion by 2032 as Precision Oncology and Multi-Omics Adoption Accelerate - GlobeNewswire Inc.
Barings LLC Sells 77,747 Shares of Qiagen N.V. $QGEN - MarketBeat
Qiagen stock trades steady as investors weigh recent earnings and molecular diagnostics demand - ad-hoc-news.de
Qiagen stock reflects steady diagnostics demand as earnings and cash flow support investment cycle - ad-hoc-news.de
QIAGEN Highlights Molecular Testing Solutions Supporting Response to Growing U.S. Cyclospora Outbreak - BioSpace
Qiagen highlights testing tools amid U.S. cyclosporiasis outbreak - Investing.com UK
Qiagen highlights testing tools amid U.S. cyclosporiasis outbreak By Investing.com - Investing.com South Africa
Qiagen Highlights Molecular Testing Solutions Supporting Response to Growing U.S. Cyclospora Outbreak - marketscreener.com
Qiagen stock holds steady as diagnostics demand supports the long-term story - Ad Hoc News
QIAGEN N.V. to release Q2 2026 results on August 5 - scanx.trade
Berenberg Downgrades Qiagen Rating, Price Target Amid Rising Competition, Growth Concerns - Moomoo
QIAGEN N.V. to Release Results for Q2 2026 and Hold Webcast - Yahoo Finance
Qiagen stock holds steady as investors track the business - ad-hoc-news.de
Berenberg Bank Maintains Qiagen NV(QGEN.US) With Hold Rating, Maintains Target Price $45.74 - Moomoo
QIAGEN Expands QIAstat-Dx Bloodstream Infection Testing Menu in Europe - BioSpace
Qiagen Is Attracting Billion-Dollar Takeover Interest! - Smartkarma
Qiagen launches bloodstream infection test panel in Europe By Investing.com - Investing.com India
USF157.USD Bond Profile — Key Metrics - TradingView
Enterprise value to revenue forward of Qiagen N.V. – NYSE:QGEN - TradingView
Qiagen (QGEN) Unveils New Bloodstream Infection Testing Panel in Europe - GuruFocus
Qiagen launches bloodstream infection test panel in Europe - Investing.com UK
Qiagen launches new bloodstream infection panel in Europe - StreetInsider
Berenberg cuts Qiagen stock rating on competitive pressures - Investing.com UK
8.61%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):